Kendall Law Group Investigates BioForm Medical, Inc. on Behalf of Shareholders

Kendall Law Group, founded by a former federal judge, is investigating the proposed acquisition of BioForm Medical, Inc (NASDAQ: BFRM) (“BioForm”) by Merz Pharma Group (“Merz”), a privately-held company based in Frankfurt, Germany. The investigation concerns whether the consideration to be paid to shareholders in this transaction is unfair and substantially below the fair or inherent value of the company. Also, the investigation will focus on whether the Board of Directors of BFRM may have breached their fiduciary duties by entering into an agreement with deal protection devices that will likely prevent other superior offers. The deal which essentially takes BioForm private, is scheduled to close within the first quarter of 2010.

On January 4, 2010, BioForm announced that it has reached an agreement to sell the Company to Merz in a deal for approximately $253 million based on outstanding shares of BioForm common stock. The transaction contains a restriction on solicitation of alternative proposals, public disclosures and other matters. It also calls for an eight million dollar termination fee to be paid by BioForm as well as allowance for a “short form” process pursuant to applicable Delaware law, which would not require the consent of shareholders if other conditions have been met.

If you are a current holder of BioForm and have additional information regarding the proposed transaction, or would like to discuss your rights as a shareholder, contact Scott Kendall at 877-744-3728 or by email at skendall@kendalllawgroup.com. Kendall Law Group has substantial experience representing investors in mergers and acquisitions nationwide. Lawyers at the firm include a former United States Attorney, federal judicial law clerk, a former state and federal judge, in addition to experienced securities lawyers.

Bioform Medical (MM) (NASDAQ:BFRM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024